Randomized Trialmoderate evidence
Efficacy and safety of avexitide for treatment of hypoglycemia following bariatric and other upper gastrointestinal surgeries: a phase 2b study.
Metabolism: clinical and experimental·September 15, 2026·PMID 42744082
Why it mattersPost-bariatric hypoglycemia affects up to 30% of RYGB patients and lacks approved pharmacotherapy. Avexitide directly targets the GLP-1 hypersecretion underlying the condition, offering a mechanism-based treatment that could reduce severe neuroglycopenic events and improve daily functioning.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled